LM22A-4 is a small molecule agonist of the TrkB receptor, which plays a key role in neuronal survival, growth, and synaptic plasticity. It is primarily investigated for its neuroprotective and neurorestorative properties. The compound has shown potential in preclinical studies for treating neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease by enhancing brain-derived neurotrophic factor (BDNF) signaling pathways. It has also been studied in models of traumatic brain injury and stroke, where it helps reduce neuronal damage and improve cognitive and motor functions. Due to its ability to cross the blood-brain barrier, LM22A-4 is considered a promising candidate for central nervous system therapeutics. Research is ongoing to evaluate its efficacy and safety in chronic neurological disorders.